Susquehanna Fundamental Investments’s Autolus Therapeutics AUTL Stock Holding History

Susquehanna Fundamental Investments’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$201K	Sell	48,250 -18,077	-27%	-$76K	﹤0.01%	1366
2021 Q4	$344K	Sell	66,327 -33,323	-33%	-$200K	0.01%	1073
2021 Q3	$653K	Buy	99,650 +36,700	+58%	+$232K	0.01%	1075
2021 Q2	$418K	Buy	+62,950	New	+$391K	0.01%	1231

Other funds holding AUTL

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Susquehanna Fundamental Investments's AUTL Position: Q1 2022 in Review

Susquehanna Fundamental Investments reduced its Autolus Therapeutics (AUTL) stake by 27% in Q1 2022, selling an estimated $76K and leaving 48,250 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

Susquehanna Fundamental Investments first reported a position in AUTL in Q2 2021 and has held it in 4 quarters since. The position peaked at $653K in Q3 2021. 66 funds tracked by Wall St. Rank hold AUTL as of Q1 2022.

Susquehanna Fundamental Investments held 48,250 shares of Autolus Therapeutics worth $201K as of Q1 2022.
Susquehanna Fundamental Investments sold 18,077 Autolus Therapeutics shares in Q1 2022, an estimated $76K.
Autolus Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1366 holding.
Susquehanna Fundamental Investments first reported a position in Autolus Therapeutics in Q2 2021 and has held it in 4 quarters since.
Susquehanna Fundamental Investments's Autolus Therapeutics position peaked at $653K in Q3 2021.
66 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.